Elutia Inc.

Elutia Inc. is a medical device company specializing in proprietary drug-eluting biomaterial platforms designed to enhance surgical reconstruction and cardiovascular repair. The company develops next-generation allograft and extracellular matrix products that integrate biologic materials with extended antibiotic release capabilities, addressing post-surgical complications and improving patient outcomes in reconstructive and cardiovascular procedures. Core product lines include SIMPLIDERM, a high-performance allograft for soft tissue reconstruction; PROXICOR PC and PROXICOR CTR engineered extracellular matrices for cardiovascular repair; VASCURE for vascular applications; and TYKE for pediatric cardiovascular use. Elutia's platform enables surgeons to perform complex reconstructive procedures using natural, regenerative materials while leveraging controlled drug delivery to reduce infection risk and optimize healing. The company positions itself at the intersection of drugs, devices, and biomatrices, focusing on solving challenges inherent to traditional medical implants through biocompatible design. Founded by C. Randal Mills, PhD., Elutia operates from Gaithersburg, Maryland, and engages in direct surgeon and institution outreach through digital education webinars and sales representative networks. The company's approach emphasizes patient-centric outcomes and long-term tissue remodeling rather than purely synthetic alternatives.